Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFIRINOX and Gemcitabine Chemoradiotherapy in Borderline Resectable Pancreatic Cancer
NCT01897454Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Jan 2012
- Primary completion
- Nov 2021
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Albert Einstein College of Medicine. Started Jan 2012; status: terminated.
02
Drugs
fluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01897454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897454.